The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetics (PK) of ibrutinib in patients with chronic lymphocytic leukemia (CLL).
Juthamas Sukbuntherng
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Purvi Jejurkar
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Stephen Chan
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Anh L. Tran
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Davina Moussa
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
David Loury
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics